Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    18321465 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Intravitreal Injections of rhuFab V2 in Combination With Visudyne in Subjects With Age Related Macular Degeneration (AMD)
Condition: Age-Related Maculopathy
Intervention: Drug: rhuFab V2 (ranibizumab)

Indicates status has not been verified in more than two years